$89.50
2.08% yesterday
NYSE, Feb 21, 10:12 pm CET
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$89.50
-6.74 7.00% 1M
-26.53 22.86% 6M
-9.98 10.03% YTD
-38.62 30.14% 1Y
+13.13 17.19% 3Y
+10.99 13.99% 5Y
+33.91 61.00% 10Y
NYSE, Closing price Fri, Feb 21 2025
+1.82 2.08%
ISIN
US58933Y1055
Symbol
MRK
Sector
Industry

Key metrics

Market capitalization $226.40b
P/E (TTM) P/E ratio 13.29
P/S ratio (TTM) P/S ratio 3.52
P/B ratio (TTM) P/B ratio 5.09
Dividend yield 3.49%
Last dividend (FY24) $3.12
Revenue growth (TTM) Revenue growth 7.41%
Revenue (TTM) Revenue $64.30b
EBIT (operating result TTM) EBIT $21.68b
Cash position $14.64b
EPS (TTM) EPS $6.73
P/E forward 14.12
P/S forward 3.95
EV/Sales forward 4.31
Short interest 1.17%
Show more

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Merck & Co. forecast:

17x Buy
65%
9x Hold
35%

Analyst Opinions

26 Analysts have issued a Merck & Co. forecast:

Buy
65%
Hold
35%

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
64,304 64,304
7% 7%
100%
- Direct Costs 15,675 15,675
12% 12%
24%
51,863 51,863
23% 23%
81%
- Selling and Administrative Expenses 10,705 10,705
64% 64%
17%
- Research and Development Expense 16,248 16,248
43% 43%
25%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 21,676 21,676
612% 612%
34%
Net Profit 17,117 17,117
4,590% 4,590%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Negative
The Motley Fool
about 10 hours ago
It's been a rough start to 2025 for Merck (MRK 2.08%) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with 7% revenue growth and earnings per share (EPS) of $1.72 for the quarter ended Dec. 31, weak sales in China and soft forward guidance were seen as a disappointment.
Neutral
Business Wire
2 days ago
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Merck & Co (“Merck” or the “Company”) (NYSE: MRK) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MERCK & CO (MRK), CLICK HERE TO INQUIRE ABOU...
Positive
Seeking Alpha
2 days ago
Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. In this article, I highlight 2 such names, both of which are trading at discounted valuations compared to historical norms. Both offer high yields and carry strong balance sheets, making them dividend juggernauts worth considering for potentially strong total returns.
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Robert Davis
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today